Status:
COMPLETED
A Study of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Solid Tumors
Eligibility:
All Genders
20+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess the dose limiting toxicity (DLT) of BMS-582664 and the maximum tolerated dose(MTD) in subjects with advanced or metastatic solid tumors.
Eligibility Criteria
Inclusion
- Patients must have measurable disease
- Documented failure to standard therapies exist, or which are determined to be inappropriate by the investigator
- ECOG PS: 0-1
Exclusion
- Subjects with centrally located squamous cell carcinoma of the lung
Key Trial Info
Start Date :
October 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT00390936
Start Date
October 1 2007
End Date
March 1 2010
Last Update
January 25 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Sunto-Gun, Shizuoka, Japan, 411-8777